Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Law & Politics

9 Dec 2022

Health Canada Releases Guidelines for Psychedelic Therapy

Health Canada has released a Notice to Stakeholders, outlining its expectations regarding risk-management measures for clinical trials involving psychedelic-assisted psychotherapy....

By Jason Najum

Law & Politics

1 Dec 2022

DEA Increases Production Quotas for Psychedelics

The Drug Enforcement Administration (DEA) has released its production quotas for 2023, announcing an increase in the permitted quantity of psychedelic compounds manufactured for research purposes....

By Jason Najum

Law & Politics

18 Nov 2022

Psychedelics Making Progress in U.S. Congress

It’s been a big 24 hours for the advancement of psychedelics....

By Jason Najum

Breaking News

6 Oct 2022

Breaking News: Alberta 1st Province to Regulate Psychedelic Therapy

In big news for access to mental health treatments, Alberta has become the first Canadian province to regulate the use of psychedelics for therapy treatment....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

28 Sep 2022

Atai Life Sciences Launches Phase 1 MDMA Trial

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01...

By Jason Najum

Industry

8 Sep 2022

MindMed Faces Tough IP Questions (and Publishes Positive Trial Results)

MindMed’s been in the news as of late....

By Jason Najum

Finance, Industry

1 Sep 2022

Cathie Wood’s ARK Invest Releases Psychedelic Research Report

Cathie Wood and the ARK Invest team have released a full report on the psychedelic sector and investment landscape....

By Jason Najum

Industry

24 Aug 2022

A Look at GH Research’s Financial and Business Results

GH Research owns the title of the most low-key player in the psychedelic medicine space....

By Jason Najum

Science

24 Aug 2022

New Study Shows Psilocybin Reduces Drinking in 83% of Patients

Conducted by researchers at NYU Langone, one of the nation's premier academic medical centers, a new study has just been released on the positive effects of psilocybin on alcohol addiction....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.